2024³â 12¿ù 23ÀÏ ¿ù¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation

KIOXIA CM7 Series Enterprise SSD Controller Cryptographic Module Meets Latest Security Requirements of NIST Cryptographic Module Validation Program
´º½ºÀÏÀÚ: 2024-12-23

TOKYO -- Kioxia Corporation, a world leader in memory solutions, announced that the cryptographic module used in KIOXIA CM7 Series PCIe® 5.0 NVMe™ Enterprise SSDs has been validated to meet Federal Information Processing Standard (FIPS) 140-3, Level 2 for cryptographic modules.

The FIPS 140-3 standard specifies a set of security requirements of the Cryptographic Module Validation Program administered by the National Institute of Standards and Technology (NIST), used as a security metric for federal agencies to procure validated IT equipment. Companies and federal agencies may prefer or may now be required to deploy newer, more stringent government standards - which SSDs validated to FIPS 140-3 requirements would meet. Compared to the previous FIPS 140-2 requirements, 140-3 provides higher standards for SSDs, including a stronger authentication method and updated implementation guidance.

Kioxia brought PCIe 5.0 technology to server and storage applications with the KIOXIA CM7 Series NVMe SSD. Targeted at enterprise applications and use cases - including artificial intelligence, high-performance computing, online transaction processing database, and data warehousing - KIOXIA CM7 Series drives bring enterprise performance, reliability and security to data center servers and storage.

KIOXIA CM7 Series SSD Key Features include:

· PCIe 5.0 compliant NVMe SSDs in 2.5-inch(1) and E3.S SSD form factors
· Dual and single-port support
· Read-intensive and mixed-use endurances
· Capacities from 1.6 terabytes (TB) to 30.72 TB (15.36 TB in E3.S form factor)
· Security options include: sanitize instant erase (SIE) (2), TCG Opal self-encrypting drive (SED) (3) and SED utilizing FIPS 140-3 Level 2 module

Notes:
(1) “2.5-inch” indicates the form factor of the SSD. It does not indicate the drive's physical size.
(2) SIE optional model supports Crypto Erase, which is a standardized feature defined by the technical committees (SCSI) of INCITS (the InterNational Committee for Information Technology Standards).
(3) SED optional model supports TCG Opal and Ruby SSCs. It does not support some features of TCG Opal SSC.

* Definition of capacity: Kioxia Corporation defines a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes and a terabyte (TB) as 1,000,000,000,000 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary.
* Security optional models are not available in all countries due to export and local regulations.

* PCIe is a registered trademark of PCI-SIG.
* NVMe is a registered or unregistered trademark of NVM Express, Inc. in the United States and other countries.
* All other company names, product names and service names may be trademarks of third-party companies.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles Certification
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation
CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Severe Atopic Dermatitis
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine at ESMO-IO 2024
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus
Abu Dhabi¡¯s Technology Innovation Institute Inaugurates Open-Source AI Summit with Critical Discussions on the Future of AI

 

DNP Achieves Fine Pattern Resolution on EUV Lithography Photomasks for...
Octapharma Injects Efficiency Into Its Supply Chain With Kinaxis
Kioxia Develops OCTRAM (Oxide-Semiconductor Channel Transistor DRAM) T...
Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance...
SES Equips Peruvian Air Force with High-throughput Connectivity via SE...
SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO...
NetApp¡¯s 2024 Data Complexity Report Reveals AI¡¯s Make or Break Year...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..